Table 1. Patient and tumor characteristics.
| BCG Connaught (n=957) | BCG Tice (n=1142) | Total (n = 2099) | ||
|---|---|---|---|---|
| Age | <70 | 556 (58.1%) | 638 (55.9%) | 1194 (56.9%) |
| >70 | 401 (41.9%) | 504 (44.1%) | 905 (43.1%) | |
| Gender | Male | 792 (82.8%) | 928 (81.3%) | 1720 (81.9%) |
| Female | 165 (17.2%) | 214 (18.7%) | 379 (18.1%) | |
| Tumor status | Primary | 835 (87.3%) | 1024 (89.7%) | 1859 (88.6%) |
| Recurrent | 122 (12.8%) | 118 (10.3%) | 240 (11.4%) | |
| Previous intravesical chemotherapy | No | 913 (95.4%) | 1066 (93.4%) | 1979 (94.3%) |
| Yes | 44 (4.6%) | 76 (6.6%) | 120 (5.7%) | |
| Number of tumors | Single | 381 (45.5%) | 420 (36.9%) | 801 (40.5%) |
| Multiple | 457 (54.5%) | 719 (63.1%) | 1176 (59.5%) | |
| Missing | 119 | 3 | 122 | |
| Largest tumor size | <3cm | 557 (75.0%) | 440 (70.3%) | 997 (72.8%) |
| >3cm | 186 (25.0%) | 186 (29.7%) | 372 (27.2%) | |
| Missing | 214 | 516 | 730 | |
| Concomitant CIS | No | 731 (76.4%) | 841 (73.6%) | 1572 (74.9%) |
| Yes | 226 (23.6%) | 301 (26.4%) | 527 (25.1%) | |
| Restaging TUR before BCG | No | 582 (60.8%) | 482 (42.2%) | 1064 (50.7%) |
| Yes | 303 (31.7%) | 558 (48.9%) | 861 (41.0%) | |
| Missing | 72 (7.5%) | 102 (8.9%) | 174 (8.3%) | |
| Risk factors for recurrence | 0 | 278 (37.5%) | 260 (41.5%) | 538 (39.3%) |
| 1 | 347 (46.8%) | 284 (45.4%) | 631 (46.1%) | |
| 2 | 117 (15.8%) | 82 (13.1%) | 199 (14.6%) | |
| Missing | 215 | 516 | 731 | |
| Risk factors for progression | 0 | 234 (31.5%) | 162 (25.9%) | 396 (28.9%) |
| 1 | 340 (45.8%) | 294 (47.0%) | 634 (46.3%) | |
| 2 | 142 (19.1%) | 136 (21.7%) | 278 (20.3%) | |
| 3 | 27 (3.6%) | 34 (5.4%) | 61 (4.5%) | |
| Missing | 214 | 516 | 730 | |
| Risk factors for survival | 0 | 332 (44.7%) | 212 (33.9%) | 544 (39.7%) |
| 1 | 324 (43.6%) | 319 (51.0%) | 643 (47.0%) | |
| 2 | 87 (11.7%) | 95 (15.2%) | 182 (13.3%) | |
| Missing | 214 | 516 | 730 | |
| Maintenance | No | 397 (41.5%) | 937 (82.1%) | 1334 (63.6%) |
| Yes | 560 (58.5%) | 205 (17.9%) | 765 (36.4%) |